Position in EXEL
as of Jun 30, 2026
· filed Jul 20, 2026
Position Value
$2,344,146
+$2,091,696 QoQ
Shares Held
43,083
+632.0% QoQ
Ownership
0.017%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#252
of 754 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GATEWAY INVESTMENT ADVISERS LLC holds $83,759,285 across 16 Biotechnology names. EXEL ranks #4 (2.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
|
365,000 | $38,916,300 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
67,289 | $33,424,464 | |
| 3 | INCY |
Incyte Corp
|
23,398 | $2,652,397 | |
| 4 | EXEL |
Exelixis, Inc.
This page
|
43,083 | $2,344,146 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
22,728 | $1,300,496 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
4,123 | $993,519 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
2,900 | $872,987 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
8,111 | $634,847 |
All Filings in EXEL
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,344,146 | 43,083 | Shares | Sole | 2026-07-20 | |
| 2026-03-31 | $252,450 | 5,886 | Shares | Sole | 2026-04-13 | |
| No filing history on record for this holder in this stock. | ||||||